[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @BioBoyScout BioBoyScout BioBoyScout posts on X about $arwr, $arwrs, $41b, science the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::3017621038/interactions)  - X Week XXXXX -XX% - X Month XXXXXX +2,065% - X Months XXXXXX +356% - X Year XXXXXX -XX% ### Mentions: X [#](/creator/twitter::3017621038/posts_active)  - X Week XX +82% - X Month XX +1,200% - X Months XX +400% - X Year XX +3.90% ### Followers: XXXXX [#](/creator/twitter::3017621038/followers)  - X Week XXXXX +0.43% - X Month XXXXX +2.50% - X Months XXXXX +6% - X Year XXXXX +11% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::3017621038/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) **Social topic influence** [$arwr](/topic/$arwr) #2, [$arwrs](/topic/$arwrs) #1, [$41b](/topic/$41b) #3, [science](/topic/science), [threshold](/topic/threshold), [future](/topic/future), [compound](/topic/compound), [business](/topic/business), [$alny](/topic/$alny), [$ions](/topic/$ions) **Top accounts mentioned or mentioned by** [@rnaianalyst](/creator/undefined) [@geneinvesting](/creator/undefined) [@arrowheadpharma](/creator/undefined) [@superduperdrugs](/creator/undefined) [@bowtiedbiotech](/creator/undefined) [@jmaraganore](/creator/undefined) [@biomedicalrx](/creator/undefined) [@paulbiogeek](/creator/undefined) [@bikerieder](/creator/undefined) [@biotech2k1](/creator/undefined) [@skathire](/creator/undefined) [@leftyt75](/creator/undefined) [@3idwarrant](/creator/undefined) [@alnylam](/creator/undefined) [@artsstocks](/creator/undefined) [@grok](/creator/undefined) [@otsociety](/creator/undefined) [@sanctuarybio](/creator/undefined) [@bioclouseau](/creator/undefined) [@genbio](/creator/undefined) **Top assets mentioned** [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) ### Top Social Posts Top posts by engagements in the last XX hours "2/8 The big takeaway: $ARWR's plozasiran hit the XXX mg/dL threshold in a far larger % of patient simulations. Thats the cutoff tied to lower pancreatitis risk. Clinically and commercially meaningful and still barely modeled by sell-side" [X Link](https://x.com/BioBoyScout/status/1996671098641900013) 2025-12-04T20:01Z 4003 followers, XXX engagements "3/8 Why it matters for valuation: stronger efficacy better payer access higher price capture faster uptake in FCS bigger early cash flows. This increases $ARWRs near-term revenue AND improves confidence in extrahepatic TRiM" [X Link](https://x.com/BioBoyScout/status/1996671100131201499) 2025-12-04T20:01Z 4001 followers, XXX engagements "4/8 The sim also strengthens the entire TRiM platform. A clean win in a tough metabolic disease raises PoS across $ARWRs other TRiM programs: liver muscle pulmonary and adipose. Sell-side is still modeling these like unrelated one-offs (shame)" [X Link](https://x.com/BioBoyScout/status/1996671101531783213) 2025-12-04T20:01Z 3999 followers, XXX engagements "5/8 Most analysts still miss the biggest point: REDEMPLOs performance boosts the platform premium. TRiM now has validated clinical potency across 5+ tissues. That de-risks multiple future drugs and justifies a far higher EV for $ARWR" [X Link](https://x.com/BioBoyScout/status/1996671103029408142) 2025-12-04T20:01Z 3999 followers, XXX engagements "6/8 With stronger REDEMPLO data the model presented earlier should increase: Uptake & persistence Price bands Probability of label expansion PoS for follow-on metabolic/lipid programs All of this mechanically pushes valuation towards the $41B range" [X Link](https://x.com/BioBoyScout/status/1996671104619106762) 2025-12-04T20:01Z 4006 followers, XXX engagements "8/8 Bottom line: the Monte Carlo data directly strengthens the 10-year revenue curve and boosts TRiMs intangible EV. Put those together and the $41B valuation for $ARWR isnt aggressive its realistic" [X Link](https://x.com/BioBoyScout/status/1996671108020379739) 2025-12-04T20:01Z 4004 followers, 1239 engagements "8/10 Time horizon bias. Platform biotechs compound for decades not one product cycle. Truncate the long tail and youll always undervalue the business. $ARWR" [X Link](https://x.com/BioBoyScout/status/1998463021706887671) 2025-12-09T18:41Z 4013 followers, XXX engagements "Dropping a new note on why sell-side keeps undervaluing $ARWR. TRiMs multi-tissue reach best-in-class science and massive pipeline optionality arent in their models. Arrowheads real Enterprise Value is far higher a $41B+ MC is now justified" [X Link](https://x.com/BioBoyScout/status/1993671684612845605) 2025-11-26T13:22Z 4012 followers, 12.7K engagements "1/8 New analysis out: a Monte Carlo sim comparing plozasiran vs olezarsen shows REDEMPLO drives deeper & more reliable TG reductions across all scenarios. Thats a major win for $ARWR & a sign the Street is still underestimating TRiMs clinical consistency" [X Link](https://x.com/BioBoyScout/status/1996671097299722569) 2025-12-04T20:01Z 4012 followers, 2018 engagements "7/8 Lastly dont ignore $ARWR's partnership leverage. Better efficacy higher milestone capture + stronger royalty economics across Takeda Amgen GSK and Sarepta programs. This is nowhere in consensus numbers" [X Link](https://x.com/BioBoyScout/status/1996671106305217014) 2025-12-04T20:01Z 4012 followers, 1100 engagements "6/10 Extrahepatic RNAi is still mispriced for $ARWR. Sarepta validating both muscle and pulmonary TRiM is huge. Thats not high risk science thats pharma-level validation" [X Link](https://x.com/BioBoyScout/status/1998463018368200814) 2025-12-09T18:41Z 4013 followers, XXX engagements "7/10 $ARWR partnerships get modeled by BofA as cash flows only. Missing: Takeda Amgen GSK Sarepta all de-risk the platform. That should lift PoS speed and EV across the pipeline" [X Link](https://x.com/BioBoyScout/status/1998463019987226883) 2025-12-09T18:41Z 4013 followers, XXX engagements "9/10 Thats why $ARWR is totally miscomped. The right peers are $ALNY and $IONS platforms that repeatedly generate drugs and earn higher multiples" [X Link](https://x.com/BioBoyScout/status/1998463023363600721) 2025-12-09T18:41Z 4013 followers, XXX engagements "10/ Bottom line: the BofA note on $ARWR isnt bearish its incomplete. Add platform reuse PoS uplift extrahepatic scale and intangible EV and a $41B valuation isnt aggressive. Its simple clean math and it's about time" [X Link](https://x.com/BioBoyScout/status/1998463025058128067) 2025-12-09T18:41Z 4013 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BioBoyScout BioBoyScout
BioBoyScout posts on X about $arwr, $arwrs, $41b, science the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX -XX%
- X Month XXXXXX +2,065%
- X Months XXXXXX +356%
- X Year XXXXXX -XX%
Mentions: X #
- X Week XX +82%
- X Month XX +1,200%
- X Months XX +400%
- X Year XX +3.90%
Followers: XXXXX #
- X Week XXXXX +0.43%
- X Month XXXXX +2.50%
- X Months XXXXX +6%
- X Year XXXXX +11%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks finance
Social topic influence $arwr #2, $arwrs #1, $41b #3, science, threshold, future, compound, business, $alny, $ions
Top accounts mentioned or mentioned by @rnaianalyst @geneinvesting @arrowheadpharma @superduperdrugs @bowtiedbiotech @jmaraganore @biomedicalrx @paulbiogeek @bikerieder @biotech2k1 @skathire @leftyt75 @3idwarrant @alnylam @artsstocks @grok @otsociety @sanctuarybio @bioclouseau @genbio
Top assets mentioned Arrowhead Research Corporation (ARWR) Alnylam Pharmaceuticals, Inc. (ALNY) Ionis Pharmaceuticals, Inc. Common Stock (IONS)
Top Social Posts
Top posts by engagements in the last XX hours
"2/8 The big takeaway: $ARWR's plozasiran hit the XXX mg/dL threshold in a far larger % of patient simulations. Thats the cutoff tied to lower pancreatitis risk. Clinically and commercially meaningful and still barely modeled by sell-side"
X Link 2025-12-04T20:01Z 4003 followers, XXX engagements
"3/8 Why it matters for valuation: stronger efficacy better payer access higher price capture faster uptake in FCS bigger early cash flows. This increases $ARWRs near-term revenue AND improves confidence in extrahepatic TRiM"
X Link 2025-12-04T20:01Z 4001 followers, XXX engagements
"4/8 The sim also strengthens the entire TRiM platform. A clean win in a tough metabolic disease raises PoS across $ARWRs other TRiM programs: liver muscle pulmonary and adipose. Sell-side is still modeling these like unrelated one-offs (shame)"
X Link 2025-12-04T20:01Z 3999 followers, XXX engagements
"5/8 Most analysts still miss the biggest point: REDEMPLOs performance boosts the platform premium. TRiM now has validated clinical potency across 5+ tissues. That de-risks multiple future drugs and justifies a far higher EV for $ARWR"
X Link 2025-12-04T20:01Z 3999 followers, XXX engagements
"6/8 With stronger REDEMPLO data the model presented earlier should increase: Uptake & persistence Price bands Probability of label expansion PoS for follow-on metabolic/lipid programs All of this mechanically pushes valuation towards the $41B range"
X Link 2025-12-04T20:01Z 4006 followers, XXX engagements
"8/8 Bottom line: the Monte Carlo data directly strengthens the 10-year revenue curve and boosts TRiMs intangible EV. Put those together and the $41B valuation for $ARWR isnt aggressive its realistic"
X Link 2025-12-04T20:01Z 4004 followers, 1239 engagements
"8/10 Time horizon bias. Platform biotechs compound for decades not one product cycle. Truncate the long tail and youll always undervalue the business. $ARWR"
X Link 2025-12-09T18:41Z 4013 followers, XXX engagements
"Dropping a new note on why sell-side keeps undervaluing $ARWR. TRiMs multi-tissue reach best-in-class science and massive pipeline optionality arent in their models. Arrowheads real Enterprise Value is far higher a $41B+ MC is now justified"
X Link 2025-11-26T13:22Z 4012 followers, 12.7K engagements
"1/8 New analysis out: a Monte Carlo sim comparing plozasiran vs olezarsen shows REDEMPLO drives deeper & more reliable TG reductions across all scenarios. Thats a major win for $ARWR & a sign the Street is still underestimating TRiMs clinical consistency"
X Link 2025-12-04T20:01Z 4012 followers, 2018 engagements
"7/8 Lastly dont ignore $ARWR's partnership leverage. Better efficacy higher milestone capture + stronger royalty economics across Takeda Amgen GSK and Sarepta programs. This is nowhere in consensus numbers"
X Link 2025-12-04T20:01Z 4012 followers, 1100 engagements
"6/10 Extrahepatic RNAi is still mispriced for $ARWR. Sarepta validating both muscle and pulmonary TRiM is huge. Thats not high risk science thats pharma-level validation"
X Link 2025-12-09T18:41Z 4013 followers, XXX engagements
"7/10 $ARWR partnerships get modeled by BofA as cash flows only. Missing: Takeda Amgen GSK Sarepta all de-risk the platform. That should lift PoS speed and EV across the pipeline"
X Link 2025-12-09T18:41Z 4013 followers, XXX engagements
"9/10 Thats why $ARWR is totally miscomped. The right peers are $ALNY and $IONS platforms that repeatedly generate drugs and earn higher multiples"
X Link 2025-12-09T18:41Z 4013 followers, XXX engagements
"10/ Bottom line: the BofA note on $ARWR isnt bearish its incomplete. Add platform reuse PoS uplift extrahepatic scale and intangible EV and a $41B valuation isnt aggressive. Its simple clean math and it's about time"
X Link 2025-12-09T18:41Z 4013 followers, XXX engagements